MCID: LSH001
MIFTS: 64

Leishmaniasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Leishmaniasis

MalaCards integrated aliases for Leishmaniasis:

Name: Leishmaniasis 12 74 20 54 42 3 44 15 17 71 32
Post-Kala-Azar Dermal Leishmaniasis 12 71
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 12
Post Kala-Azar Dermal Leishmaniasis 12
Leishmaniasis, Cutaneous 71
Cutaneous Leishmaniasis 20
Leishmaniasis, Visceral 71
Visceral Leishmaniasis 20
Kala-Azar 20

Classifications:



Summaries for Leishmaniasis

MedlinePlus : 42 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver, and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Leishmaniasis is found in parts of about 88 countries. Most of these countries are in the tropics and subtropics. It is possible but very unlikely that you would get this disease in the United States. But you should be aware of it if you are traveling to the Middle East or parts of Central America, South America, Asia, Africa or southern Europe. Treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. The best way to prevent the disease is to protect yourself from sand fly bites: Stay indoors from dusk to dawn, when sand flies are the most active Wear long pants and long-sleeved shirts when outside Use insect repellent and bed nets as needed Centers for Disease Control and Prevention

MalaCards based summary : Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to mucocutaneous leishmaniasis and cutaneous leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Leishmaniasis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Lidocaine and deoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, spleen and t cells, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

GARD : 20 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Visceral disease can be deadly without proper treatment. Leishmaniasis is found in parts of the Middle East, Central America, South American, Asia, Africa, and southern Europe. Most of these countries are in the tropics and subtropics. It is possible but very unlikely to get this disease in the United States.

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Wikipedia : 74 Leishmaniasis is a disease caused by parasites of the Leishmania type. It is spread by the bite of... more...

Related Diseases for Leishmaniasis

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 989)
# Related Disease Score Top Affiliating Genes
1 mucocutaneous leishmaniasis 32.8 TNF LMLN IL5 IL4 IL10 IFNG
2 cutaneous leishmaniasis 32.6 TNF TLR4 TLR2 SLC11A1 NOS2 LMLN
3 visceral leishmaniasis 32.5 TNF TLR4 TLR2 SLC11A1 NOS2 LMLN
4 chagas disease 31.3 TNF TLR4 TLR2 TGFB1 NOS2 IL4
5 hemophagocytic lymphohistiocytosis 31.2 TNF IL10 IFNGR1 IFNG
6 sleeping sickness 31.2 NOS2 LMLN IL10
7 exanthem 31.1 TNF IL1B IL10 IFNG
8 disease by infectious agent 31.1 TNF TLR4 TLR2 SLC11A1 IL4 IL1B
9 trypanosomiasis 31.1 TNF IL4 IL1B IL1A IL10 IFNG
10 alopecia 31.0 TNF IL4 IL1B IFNG
11 lepromatous leprosy 30.9 TNF TLR2 IL4 IL10 IFNGR1 IFNG
12 histoplasmosis 30.9 TNF IFNG HLA-DRB1 HLA-DQA1
13 autoimmune hepatitis 30.8 TNF IL4 IL10 HLA-DRB1
14 human immunodeficiency virus infectious disease 30.8 TNF IL4 IL10 IFNG
15 acute pancreatitis 30.8 TNF TLR4 IL1B IL10
16 tuberculoid leprosy 30.8 TLR2 TGFB1 IL10 IFNG
17 chickenpox 30.8 TNF IL4 IL10 IFNG
18 hypersplenism 30.7 TLR4 IL4 IFNG
19 miliary tuberculosis 30.7 TNF IFNGR1 IFNG
20 iridocyclitis 30.7 TNF IL1B IL10
21 pemphigus 30.7 TNF IL4 IL10 HLA-DRB1
22 autoimmune vasculitis 30.7 TNF IL4 IL1B
23 allergic disease 30.7 TNF TLR4 TLR2 IL5 IL4 IL1B
24 panuveitis 30.7 TNF IL10 HLA-DRB1
25 acquired immunodeficiency syndrome 30.7 TNF RN7SL1 NOS2 ITGAM IL1B IL10
26 uveitis 30.7 TNF IL4 IL1B IL1A IL10 IFNG
27 neutropenia 30.7 TNF TLR4 ITGAM IL4 IL1B IL1A
28 leprosy 3 30.7 TNF TLR4 TLR2 SLC11A1 IL5 IL4
29 amebiasis 30.6 TNF TLR2 IL4 IL1B IL10
30 lymphadenitis 30.6 TNF TLR4 SLC11A1 IL1B IL10 IFNGR1
31 infective endocarditis 30.6 TNF TLR2 FCGR2A
32 portal hypertension 30.6 TNF TLR4 TGFB1
33 conjunctivitis 30.6 TNF IL5 IL4 IL10 IFNG
34 herpes zoster 30.6 TNF TLR2 IL10 IFNG HLA-DRB1 FCGR2A
35 cryoglobulinemia 30.6 TNF IL1B IFNG HLA-DRB1
36 pulmonary tuberculosis 30.6 TNF TLR2 SLC11A1 IL4 IL10 IFNGR1
37 diarrhea 30.6 TNF TLR4 TGFB1 IL5 IL1B IL10
38 systemic scleroderma 30.6 TNF TGFB1 IL4 IL10 IFNG
39 brucellosis 30.6 TNF TLR4 TGFB1 SLC11A1 IL4 IL10
40 spondylitis 30.6 TNF IL1B IL10 IFNG
41 bronchopneumonia 30.6 TNF TLR4 IL1B IL10
42 schistosomiasis 30.6 TNF IL5 IL4 IL1A IL10 IFNGR1
43 purpura 30.6 TNF IL4 IL1B IL10 IFNG
44 trichinosis 30.6 IL5 IL4 IL10
45 immune deficiency disease 30.6 TNF TLR2 ITGAM IL4 IL1B IL1A
46 stomatitis 30.5 TNF IL4 IL1B IL10 IFNG
47 skin disease 30.5 TNF TLR2 IL5 IL4 IL1B IL1A
48 candidiasis 30.5 TNF TLR4 TLR2 IL4 IL1B IL10
49 filariasis 30.5 TNF TLR4 TLR2 NOS2 IL5 IL10
50 urinary tract infection 30.5 TLR4 TGFB1

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis

Symptoms & Phenotypes for Leishmaniasis

Human phenotypes related to Leishmaniasis:

31 (show all 24)
# Description HPO Frequency HPO Source Accession
1 splenomegaly 31 hallmark (90%) HP:0001744
2 hepatomegaly 31 hallmark (90%) HP:0002240
3 skin ulcer 31 hallmark (90%) HP:0200042
4 abnormal bleeding 31 hallmark (90%) HP:0001892
5 papule 31 hallmark (90%) HP:0200034
6 abnormal oral mucosa morphology 31 hallmark (90%) HP:0011830
7 lymphadenopathy 31 hallmark (90%) HP:0002716
8 pancytopenia 31 hallmark (90%) HP:0001876
9 recurrent fever 31 hallmark (90%) HP:0001954
10 abnormal macrophage morphology 31 hallmark (90%) HP:0004311
11 rhinitis 31 hallmark (90%) HP:0012384
12 skin plaque 31 hallmark (90%) HP:0200035
13 night sweats 31 hallmark (90%) HP:0030166
14 anemia 31 frequent (33%) HP:0001903
15 elevated hepatic transaminase 31 frequent (33%) HP:0002910
16 pallor 31 frequent (33%) HP:0000980
17 arthralgia 31 frequent (33%) HP:0002829
18 weight loss 31 frequent (33%) HP:0001824
19 hypoalbuminemia 31 frequent (33%) HP:0003073
20 increased circulating antibody level 31 frequent (33%) HP:0010702
21 fatigue 31 occasional (7.5%) HP:0012378
22 thrombocytopenia 31 occasional (7.5%) HP:0001873
23 anorexia 31 occasional (7.5%) HP:0002039
24 leukopenia 31 occasional (7.5%) HP:0001882

UMLS symptoms related to Leishmaniasis:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Leishmaniasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 FCGR1A FCGR2A HLA-DQA1 IFNG IFNGR1 IL10
2 immune system MP:0005387 10.3 FCGR1A FCGR2A HLA-DQA1 IFNG IFNGR1 IL10
3 homeostasis/metabolism MP:0005376 10.25 FCGR2A IFNG IFNGR1 IL10 IL1A IL1B
4 digestive/alimentary MP:0005381 10.2 IFNG IFNGR1 IL10 IL4 IL5 NOS2
5 integument MP:0010771 10.1 IFNG IFNGR1 IL10 IL1A IL1B IL4
6 liver/biliary system MP:0005370 9.96 IFNG IFNGR1 IL10 IL4 IL5 NOS2
7 neoplasm MP:0002006 9.93 IFNG IFNGR1 IL10 IL1A IL1B IL5
8 respiratory system MP:0005388 9.61 IFNG IL10 IL4 IL5 NOS2 TGFB1
9 skeleton MP:0005390 9.4 FCGR1A FCGR2A IFNG IFNGR1 IL10 IL1B

Drugs & Therapeutics for Leishmaniasis

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
deoxycholic acid Approved Phase 4 83-44-3 222528
3
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
4 Anesthetics Phase 4
5 Anti-Bacterial Agents Phase 4
6 Amebicides Phase 4
7 Amphotericin B, deoxycholate drug combination Phase 4
8 Gastrointestinal Agents Phase 4
9
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
10
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
11
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
12
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
13
Tocopherol Approved, Investigational Phase 3 1406-66-2
14
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
15
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 447043
16
Nitric Oxide Approved Phase 3 10102-43-9 145068
17
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
18
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
19 Tocotrienol Investigational Phase 3 6829-55-6
20 Molgramostim Investigational Phase 3 99283-10-0
21 Gentamicins Phase 3
22 Liposomal amphotericin B Phase 3
23 Immunologic Factors Phase 3
24 Adjuvants, Immunologic Phase 3
25 interferons Phase 3
26 Vitamins Phase 3
27 Tocotrienols Phase 3
28 Tocopherols Phase 3
29 Pharmaceutical Solutions Phase 3
30 Protective Agents Phase 3
31 Respiratory System Agents Phase 3
32 Anti-Asthmatic Agents Phase 3
33 Neurotransmitter Agents Phase 3
34 Antioxidants Phase 3
35 Endothelium-Dependent Relaxing Factors Phase 3
36 Bronchodilator Agents Phase 3
37 Vasodilator Agents Phase 3
38 Cytochrome P-450 Enzyme Inhibitors Phase 3
39 Hormone Antagonists Phase 3
40 Hormones Phase 3
41
Miltefosine Approved, Investigational Phase 1, Phase 2 58066-85-6 3600
42
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
43
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
44
Coal tar Approved Phase 2 8007-45-2
45
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
46 Methyl 5-aminolevulinate Phase 2
47 Anti-Infective Agents Phase 1, Phase 2
48 Antiparasitic Agents Phase 1, Phase 2
49 Antiprotozoal Agents Phase 1, Phase 2
50 Antifungal Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
3 Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. Completed NCT01462500 Phase 4 Miltefosine
4 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
7 Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
8 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
9 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. Completed NCT00818818 Phase 4 Meglumine antimoniate
10 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
11 Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
12 A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
13 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
14 Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
15 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
16 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
17 Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
18 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
19 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
20 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
21 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
22 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
23 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
24 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
25 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
26 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
27 A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
28 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
29 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
30 Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients Completed NCT00257530 Phase 3 Imiquimod
31 Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
32 Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL) Completed NCT04340128 Phase 3 Meglumine antimoniate;Meglumine antimoniate
33 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Completed NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
34 Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial Completed NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
35 Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
36 Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
37 Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
38 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
39 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Active, not recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
40 Randomised, Open Label, Multicentre, Non-inferiority Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan Not yet recruiting NCT04268524 Phase 3
41 Efficacy and Safety of Thermotherapy in Combination With Miltefosine Compared to Meglumine Antimoniate and Miltefosine Monotherapy for the Treatment of New World Cutaneous Leishmaniasis: A Phase III, Open Label, Multicenter Randomized Trial Not yet recruiting NCT04515186 Phase 3 Meglumine Antimoniate;Miltefosine
42 Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
43 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
44 Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan Terminated NCT03208543 Phase 3
45 Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
46 Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
47 EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
48 The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
49 Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Completed NCT00233545 Phase 2 miltefosine;antimony
50 Treatment of Bolivian Cutaneous Leishmaniasis With a Combination of Oral Miltefosine Plus Topical Imiquimod 5% Completed NCT01380314 Phase 2 Miltefosine + Imiquimod;Miltefosine 150 mg x day + Placebo

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Antileishmanial [EPC]
Itraconazole
Ketoconazole
Meglumine
miltefosine
Pentamidine
Pentamidine Isethionate

Cochrane evidence based reviews: leishmaniasis

Genetic Tests for Leishmaniasis

Anatomical Context for Leishmaniasis

MalaCards organs/tissues related to Leishmaniasis:

40
Skin, Spleen, T Cells, Bone Marrow, Liver, Kidney, Monocytes

Publications for Leishmaniasis

Articles related to Leishmaniasis:

(show top 50) (show all 22317)
# Title Authors PMID Year
1
The role of senescent T cells in immunopathology. 61 42
33166035 2020
2
The diagnostic accuracy of direct agglutination test for serodiagnosis of human visceral leishmaniasis: a systematic review with meta-analysis. 42 61
33308170 2020
3
Visceral leishmaniasis in patients with lymphoma: Case reports and review of the literature. 61 42
33157924 2020
4
T cells specific to leishmania and other nonrelated microbial antigens can migrate to human leishmaniasis skin lesions. 54 61
20107484 2010
5
Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. 61 54
20404924 2010
6
Sequence analysis and PCR-RFLP profiling of the hsp70 gene as a valuable tool for identifying Leishmania species associated with human leishmaniasis in Brazil. 61 54
19913112 2010
7
Anti-iL-10 mAb protection against experimental visceral leishmaniasis via induction of Th1 cytokines and nitric oxide. 54 61
19634715 2009
8
Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes. 54 61
19040614 2009
9
In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment. 61 54
19125672 2009
10
Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis. 61 54
19037922 2008
11
Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. 61 54
18778366 2008
12
Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections. 61 54
18687297 2008
13
Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. 54 61
18444882 2008
14
CD8 cytotoxic T cells in cutaneous leishmaniasis. 61 54
18042173 2007
15
IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. 61 54
17911647 2007
16
Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? 54 61
17614975 2007
17
T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. 54 61
17710308 2007
18
Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. 54 61
17395340 2007
19
Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. 54 61
17430548 2007
20
Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome. 54 61
17218153 2007
21
IFNG and IFNGR1 gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan. 54 61
17136124 2007
22
[CD8+ cytotoxic lymphocytes in cutaneous leishmaniasis]. 61 54
17063826 2006
23
Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production. 54 61
16638143 2006
24
Crystallization and preliminary X-ray analysis of Leishmania major glyoxalase I. 54 61
16511153 2005
25
Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. 61 54
15853916 2005
26
Natural killer cells and innate immunity to protozoan pathogens. 54 61
15582528 2004
27
Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. 54 61
15569785 2004
28
The role of CD4(+)CD25(+) regulatory T cells in Leishmania infection. 54 61
12943446 2003
29
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa. 54 61
12653650 2003
30
Characterization of the immune response to Leishmania infantum recombinant antigens. 61 54
12593967 2003
31
Up-regulation of Th1-type responses in mucosal leishmaniasis patients. 61 54
12438348 2002
32
Interferon-gamma treatment induces granulomatous tissue reaction in a case of localized cutaneous leishmaniasis. 61 54
12142611 2002
33
Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp. 61 54
11953362 2002
34
Unresponsiveness of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to Leishmania guyanensis. 54 61
11555399 2001
35
Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. 54 61
11544330 2001
36
Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. 54 61
11422202 2001
37
Atypical mucocutaneous leishmaniasis caused by Leishmania braziliensis in an acquired immunodeficiency syndrome patient: T-cell responses and remission of lesions associated with antigen immunotherapy. 61 54
10446016 1999
38
Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. 61 54
9952391 1999
39
T-cell response in human leishmaniasis. 54 61
10065635 1999
40
Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. 61 54
9855627 1998
41
Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. 61 54
9596736 1998
42
Cytokine profile and pathology in human leishmaniasis. 61 54
9686192 1998
43
[Immunopathology of American tegumentary leishmaniasis]. 61 54
10205916 1998
44
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. 54 61
9472662 1998
45
Human_leishmaniasis/cytokines.bahia.br. 61 54
9686193 1998
46
Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production. 54 61
9234779 1997
47
Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. 54 61
9041358 1997
48
Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. 54 61
8832954 1996
49
Interferon-gamma in the management of infectious diseases. 54 61
7598304 1995
50
Immunogenetics in the analysis of resistance to intracellular pathogens. 61 54
7495519 1995

Variations for Leishmaniasis

Expression for Leishmaniasis

Search GEO for disease gene expression data for Leishmaniasis.

Pathways for Leishmaniasis

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 TNF TLR4 TLR2 TGFB1 SLC11A1 NOS2
2
Show member pathways
13.91 TNF TLR4 TLR2 ITGAM IL10 IFNG
3
Show member pathways
13.89 TNF TGFB1 NOS2 ITGAM IL5 IL4
4
Show member pathways
13.8 TNF TLR4 TGFB1 NOS2 IL5 IL4
5
Show member pathways
13.66 TNF TGFB1 ITGAM IL5 IL4 IL1B
6
Show member pathways
13.55 TNF TLR4 TLR2 TGFB1 ITGAM IL5
7
Show member pathways
13.49 TNF TGFB1 NOS2 ITGAM IL5 IL4
8
Show member pathways
13.37 TNF TGFB1 IL5 IL4 IL1B IL1A
9
Show member pathways
13.37 TNF TLR4 TLR2 IL4 IL1B IL1A
10
Show member pathways
13.22 TNF TLR4 TLR2 TGFB1 NOS2 IL1B
11
Show member pathways
13.04 TNF TGFB1 IL5 IL4 IL1B IL1A
12
Show member pathways
13 TNF TLR4 TLR2 IL1B IL1A IFNGR1
13 12.96 TNF TLR2 IL1B IFNGR1 IFNG HLA-DRB1
14 12.94 TGFB1 NOS2 IL5 IL4 IFNGR1 IFNG
15
Show member pathways
12.84 TNF TLR4 TLR2 NOS2 IL1B IL1A
16
Show member pathways
12.83 TNF TLR4 TLR2 TGFB1 IL1B IL1A
17
Show member pathways
12.81 TNF TLR4 TLR2 IL1B FCGR2A
18
Show member pathways
12.8 TNF IL4 IL10 IFNGR1 IFNG HLA-DRB1
19
Show member pathways
12.76 TNF TLR4 TLR2 TGFB1 IL5 IL4
20
Show member pathways
12.75 TNF IL1B IL1A IFNGR1 IFNG
21 12.72 TNF TLR2 IL4 IL1B IL10 IFNG
22
Show member pathways
12.68 TNF NOS2 IL1B IL10 IFNG
23
Show member pathways
12.68 TNF TLR4 TLR2 IL1B IL1A
24
Show member pathways
12.63 IFNGR1 IFNG HLA-DRB1 HLA-DQA1 FCGR1A
25
Show member pathways
12.53 IL5 IL4 IL10 IFNGR1 IFNG
26
Show member pathways
12.51 TNF TLR4 TLR2 TGFB1 IL5 IL4
27
Show member pathways
12.5 TNF TLR2 IL5 IL4 IL1B IFNG
28
Show member pathways
12.5 TNF TLR4 NOS2 IL1B IL1A IFNGR1
29
Show member pathways
12.46 TNF TGFB1 IL5 IL4 IL1B IL1A
30 12.41 TNF TGFB1 HLA-DRB1 HLA-DQA1
31
Show member pathways
12.41 TNF TLR4 TLR2 NOS2 IL4 IL1B
32
Show member pathways
12.4 TNF IL4 IL1B IFNG
33
Show member pathways
12.39 TNF TLR4 IL1B IL1A IFNGR1 IFNG
34 12.38 TNF TLR4 TLR2 TGFB1
35 12.38 TNF TLR4 TLR2 TGFB1 NOS2 IFNGR1
36
Show member pathways
12.34 TNF TLR4 TLR2 IL1A
37 12.34 TLR4 TLR2 ITGAM HLA-DRB1 HLA-DQA1 FCGR2A
38 12.27 TNF TGFB1 IL1B IL1A IFNGR1 IFNG
39 12.26 TNF IL1B IL1A IL10
40 12.25 TNF TLR4 IL1B IL10 FCGR2A
41 12.21 TNF ITGAM IL5 IL4 IL10 IFNG
42 12.21 TNF TGFB1 NOS2 ITGAM IL4 IL1B
43
Show member pathways
12.2 TLR4 TLR2 IL5 IL1B IL1A
44 12.19 TNF IL1B IL1A IFNG
45 12.19 TNF TLR4 TGFB1 NOS2 IL4 IL1B
46
Show member pathways
12.16 NOS2 IL4 IL1B IFNG HLA-DRB1
47 12.11 ITGAM IL10 HLA-DRB1 HLA-DQA1 FCGR2A FCGR1A
48 12.09 TNF TLR4 TLR2 TGFB1 NOS2 ITGAM
49 12.08 TLR4 NOS2 IFNGR1 IFNG
50
Show member pathways
12.07 TLR4 TLR2 TGFB1 IL4 IL1B IFNG

GO Terms for Leishmaniasis

Cellular components related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.73 TNF TLR4 TLR2 TGFB1 ITGAM HLA-DRB1
2 extracellular space GO:0005615 9.65 TNF TGFB1 ITGAM IL5 IL4 IL1B
3 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DRB1 HLA-DQA1 FCGR1A
4 integral component of plasma membrane GO:0005887 9.28 TNF TLR4 TLR2 SLC11A1 IFNGR1 HLA-DRB1

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.39 TLR4 TLR2 IL5 IL4 IL1B IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TNF TLR4 TLR2 TGFB1 SLC11A1 IL4
3 immune system process GO:0002376 10.23 TLR4 TLR2 ITGAM HLA-DRB1 HLA-DQA1 FCGR2A
4 positive regulation of transcription, DNA-templated GO:0045893 10.2 TNF TGFB1 IL5 IL4 IL1B IL10
5 negative regulation of cell proliferation GO:0008285 10.14 TLR2 TGFB1 IL1B IL1A IL10
6 defense response to bacterium GO:0042742 10.08 TNF TLR4 SLC11A1 NOS2 IL10
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.05 TNF TLR4 TGFB1 HLA-DRB1
8 positive regulation of protein phosphorylation GO:0001934 10.05 TNF TGFB1 IL1B IFNG HLA-DRB1
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF TLR4 TLR2 TGFB1 IL1B
10 response to lipopolysaccharide GO:0032496 10 TLR4 TLR2 SLC11A1 NOS2 IL1B IL10
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.99 TNF IL5 IL1B IL10
12 cellular response to lipopolysaccharide GO:0071222 9.99 TNF TLR4 NOS2 IL1B IL1A IL10
13 inflammatory response GO:0006954 9.97 TNF TLR4 TLR2 TGFB1 SLC11A1 NOS2
14 positive regulation of gene expression GO:0010628 9.96 TNF TLR4 TLR2 TGFB1 SLC11A1 IL4
15 regulation of insulin secretion GO:0050796 9.95 TNF NOS2 IL1B IFNG
16 positive regulation of inflammatory response GO:0050729 9.95 TNF TLR4 TLR2 IL1B IFNG
17 cellular response to mechanical stimulus GO:0071260 9.94 TLR4 TGFB1 IL1B
18 negative regulation of tumor necrosis factor production GO:0032720 9.93 TLR4 IL4 IL10
19 negative regulation of interleukin-6 production GO:0032715 9.93 TNF TLR4 IL10
20 apoptotic signaling pathway GO:0097190 9.93 TNF TLR4 ITGAM
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 TNF IL4 IFNG
22 positive regulation of tumor necrosis factor production GO:0032760 9.93 TLR4 TLR2 IL1A IFNGR1 IFNG
23 cellular response to organic cyclic compound GO:0071407 9.92 TNF TGFB1 IL1B
24 positive regulation of interleukin-1 beta production GO:0032731 9.92 TNF TLR4 IFNG
25 positive regulation of protein complex assembly GO:0031334 9.92 TNF TGFB1 IFNG
26 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.92 TNF TLR4 TLR2 IL1B
27 positive regulation of interferon-gamma production GO:0032729 9.92 TNF TLR4 SLC11A1 IL1B
28 positive regulation of cell division GO:0051781 9.9 TGFB1 IL1B IL1A
29 extrinsic apoptotic signaling pathway GO:0097191 9.9 TNF TGFB1 IFNG
30 negative regulation of T cell proliferation GO:0042130 9.9 TGFB1 IL10 HLA-DRB1
31 negative regulation of interferon-gamma production GO:0032689 9.9 TLR4 IL10 HLA-DRB1
32 positive regulation of interleukin-8 production GO:0032757 9.9 TNF TLR4 TLR2 IL1B
33 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.89 TNF TGFB1 IL10
34 positive regulation of interleukin-12 production GO:0032735 9.89 TLR4 TLR2 IFNG
35 positive regulation of B cell proliferation GO:0030890 9.89 TLR4 IL5 IL4
36 interferon-gamma-mediated signaling pathway GO:0060333 9.89 IFNGR1 IFNG HLA-DRB1 HLA-DQA1 FCGR1A
37 protein kinase B signaling GO:0043491 9.88 TNF TGFB1 IL1B
38 positive regulation of interleukin-10 production GO:0032733 9.88 TLR4 TLR2 IL4
39 negative regulation of mitotic cell cycle GO:0045930 9.88 TNF TGFB1 IL10
40 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.88 TNF IL1B IL1A
41 positive regulation of phagocytosis GO:0050766 9.88 TNF SLC11A1 IL1B IFNG
42 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TNF TLR4 IL1B IFNG
43 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR4 TLR2 IL1B IL1A IFNG
44 positive regulation of JAK-STAT cascade GO:0046427 9.87 TNF IL5 IL10
45 positive regulation of chemokine production GO:0032722 9.87 TNF TLR4 TLR2 IFNG
46 positive regulation of vascular endothelial growth factor production GO:0010575 9.86 TGFB1 IL1B IL1A
47 positive regulation of cytokine production GO:0001819 9.85 TNF SLC11A1 IL1A IL10 IFNG
48 negative regulation of interleukin-17 production GO:0032700 9.84 TLR4 TGFB1 IFNG
49 positive regulation of amyloid-beta formation GO:1902004 9.83 TNF IFNGR1 IFNG
50 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.82 TLR4 TLR2 IFNG

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 9.32 FCGR2A FCGR1A
2 MHC class II receptor activity GO:0032395 9.26 HLA-DRB1 HLA-DQA1
3 growth factor activity GO:0008083 9.26 TGFB1 IL5 IL4 IL10
4 cytokine activity GO:0005125 9.23 TNF TGFB1 IL5 IL4 IL1B IL1A
5 lipopolysaccharide receptor activity GO:0001875 9.16 TLR4 TLR2

Sources for Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....